chevron_leftBack
As of 13 June 2026, Acelyrin, Inc. has a market cap of $227.15M USD, ranking #20286 globally and #3336 in the United States.
It ranks #1819 in the Healthcare sector, and #353 in the Biotechnology industry.
Key Stats
Market Cap
$227.15MUSD
Enterprise Value
-$176.38MUSD
EBITDA (TTM)
-$270.06MUSD
Net Income (TTM)
-$268.52MUSD
PB Ratio
0.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Mina Kim
open_in_new
Employees
83
Founded
2020
IPO
05 May 2023
Website
acelyrin.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.9% | 10% | 2.3% | 3.7% | -49% | -48% |
News
Loading...
SLRN Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SLRN
Acelyrin Inc
ISIN: US00445A1007
Shares Out.:
Shares Outstanding:
100.954M1
Shares Float:
77.871M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
2.25 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Acelyrin, Inc.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
80K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
70K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
12K%
|
-
|
|
NYSE: IQV
|
$26.3B
11K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
11K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
8K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
21K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
20K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
19K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
19K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
12K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
11K%
|
-
|
chevron_leftBack